What is Paradigm Biopharmaceuticals's contact information?

Paradigm Biopharmaceuticals's contact information: info@paradigmbiopharma.com, sasrequests@paradigmbiopharma.com, investorrelations@paradigmbiopharma.com, +61396295566.

How many employees does Paradigm Biopharmaceuticals have?

Paradigm Biopharmaceuticals has 24 employees.

What industry does Paradigm Biopharmaceuticals belong to?

Paradigm Biopharmaceuticals is in the industry of: Pharmaceuticals, Biotechnology, Healthcare, Pharmaceutical Manufacturing.

What are Paradigm Biopharmaceuticals's official social media profiles?

Paradigm Biopharmaceuticals Linkedin Page Paradigm Biopharmaceuticals Twitter Page

What tech stack does Paradigm Biopharmaceuticals use?

Some of the popular technologies that Paradigm Biopharmaceuticals uses are: Google Analytics, WordPress, Amazon CloudFront, Amazon CloudFront CDN.

What are Paradigm Biopharmaceuticals's office addresses?

Paradigm Biopharmaceuticals has a known office at the following address: 500 Collins L2 517 Flinders Lane Melbourne, Victoria 3000, AU.

What is Paradigm Biopharmaceuticals's estimated annual revenue?

Paradigm Biopharmaceuticals's revenue is $2,136,000

What is Paradigm Biopharmaceuticals's open headcount?

Paradigm Biopharmaceuticals has no job postings yet.

What is the number of ad campaigns for Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals has no advertisements yet.

What is the number of recent news articles about Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals has 6 news articles.

Paradigm Biopharmaceuticals - Pubrio Company Profile & Intent

Paradigm Biopharmaceuticals

Australia · Pharmaceutical Manufacturing

Pharmaceuticals

Biotechnology

Healthcare

Pharmaceutical Manufacturing

Paradigm’s (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, the non-opioid PPS has genuine disease-modifying potential.

Company Insights

themarketherald.com.au · recognized_as · 2026-01-04

Open news

Paradigm Biopharma hits 25% recruitment milestone

Paradigm Biopharma reaches 25% recruitment milestone for clinical trial, faces patient headwinds entering 2026.

Paradigm Biopharmaceuticals

themarketherald.com.au · launches · 2025-11-13

Open news

Australian market update: Travel, tech, and resources in focus

ASX sees mixed performance with travel, tech, and resource sectors making headlines. Notable movements in Webjet, Renerve, DroneShield, and mineral companies.

Mineral Resources Limited

Webjet.Com.Au

Havilah Resources Limited

Win Metals

Sandfire Resources Nl

Paradigm Biopharmaceuticals

Zoono

Droneshield

Commonwealth Bank

Aristocrat

Life360

Activeport Pty Ltd

themarketherald.com.au · launches · 2025-11-13

Open news

ASX market update: Travel, tech, and resources in focus

ASX sees mixed performance across sectors, with notable movements in travel, technology, and resources stocks. Companies like Webjet, Renerve, and DroneShield experience significant price changes.

Mineral Resources Limited

Webjet.Com.Au

Havilah Resources Limited

Win Metals

Sandfire Resources Nl

Paradigm Biopharmaceuticals

Zoono

Droneshield

Commonwealth Bank

Aristocrat

Life360

Activeport Pty Ltd

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin option investors bet on downside despite price rise

Bitcoin ETF and crypto-holding firms are buying put options to hedge against potential price drops below $60,000, despite recent price increases.

Coindesk

Deribit

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin's 'Death Cross' Appears: Future Trends?

Bitcoin chart shows 'death cross' pattern, historically preceding major price drops. Despite this, ETFs see $1 billion inflow and long-term investors continue accumulating.

Coindesk

Upbit Singapore

coinreaders.com · launches · one week ago

Open news

JPMorgan: Crypto Market Structure Act likely to pass mid-year

JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.

Coindesk

J.P. Morgan

Get full access to view complete information

1 - 6 of 6

Frequently Asked Questions Regarding Paradigm Biopharmaceuticals

Company Overview

2014

Founded

Pharmaceutical Manufacturing

Industry

Australia

Location

2,784,686

Ranking

24 employees

Size

Similar Companies

Get full access to view complete information